These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17600286)

  • 1. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
    Camerini R; Ciancio A; DE Rosa A; Rizzetto M
    Ann N Y Acad Sci; 2007 Sep; 1112():368-74. PubMed ID: 17600286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymalfasin for the treatment of chronic hepatitis C infection.
    Rustgi VK
    Ann N Y Acad Sci; 2007 Sep; 1112():357-67. PubMed ID: 17600289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
    Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
    Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
    Ciancio A; Picciotto A; Giordanino C; Smedile A; Tabone M; Manca A; Marenco G; Garbagnoli P; Andreoni M; Cariti G; Calleri G; Sartori M; Cusumano S; Grasso A; Rizzi R; Gallo M; Basso M; Anselmo M; Percario G; Ciccone G; Rizzetto M; Saracco G
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1079-86. PubMed ID: 16984502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
    Marcellin P; Horsmans Y; Nevens F; Grange JD; Bronowicki JP; Vetter D; Purdy S; Garg V; Bengtsson L; McNair L; Alam J
    J Hepatol; 2007 Oct; 47(4):476-83. PubMed ID: 17629590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial results of peginterferons in combination with ribavirin.
    Craxi A; Licata A
    Semin Liver Dis; 2003; 23 Suppl 1():35-46. PubMed ID: 12934167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis C in southern Taiwan.
    Chuang WL; Yu ML; Dai CY; Chang WY
    Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C.
    Sebastiani G; Ferrari A; Boccato S; Pistis R; Alberti A
    Aliment Pharmacol Ther; 2007 Oct; 26(7):1077-82. PubMed ID: 17877515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
    Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
    Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.